Angle Says Parsortix Can Capture Circulating Tumor Cells With Broader Ability

(RTTNews) - UK-based specialist medtech company Angle Plc. (AGL.L, GAS) Monday said its Parsortix system demonstrated broader ability to capture circulating tumor cells, in comparison with other separation technologies.

The data published in the International Journal of Cancer showed the Parsortix system efficiently captures and harvests intact, viable circulating tumour cells, including EpCAM-negative CTCs, to allow for broader downstream CTC analysis.

The company noted that a rigorous evaluation by researchers at University Medical Centre Hamburg-Eppendorf of Angle's Parsortix cell separation system has demonstrated significant advantages of its size and deformability based enrichment technology, versus marker-based systems.

Klaus Pantel, co-author and chairman of department of tumour biology at UKE's Centre of Experimental Medicine said the research will play an important role in cancer diagnoses and subsequent treatment.